Figure 2.

The relationship between AdipoR1/R2 expression in tumor tissues and sunitinib response and patient survival in mRCC.

(A) The expression levels of AdipoR1 in mRCC patients with PD (n = 20) or non-PD (n = 45) during sunitinib therapy (P = .020).

(B) Kaplan–Meier curves of the progression-free survival of mRCC patients (n = 127), with regard to the expression levels of AdipoR1.

(C) Kaplan–Meier curves of the overall survival of mRCC patients, with regard to the expression levels of AdipoR1.

(D) The expression levels of AdipoR2 (n = 127) in mRCC patients with PD or non-PD during sunitinib therapy (P = .711).

(E) Kaplan–Meier curves of the progression-free survival of mRCC patients, with regard to the expression levels of AdipoR2.

(F) Kaplan–Meier curves of the overall survival of mRCC patients, with regard to the expression levels of AdipoR2.

(G) Kaplan–Meier curves of the progression-free survival of mRCC patients (n = 30), with regard to the expression levels of AdipoR1 in metastatic lesions.

(H) Kaplan–Meier curves of the overall survival of mRCC patients, with regard to the expression levels of AdipoR1 in metastatic lesions.

(I) Kaplan–Meier curves of the progression-free survival of mRCC patients (n = 30), with regard to the expression levels of AdipoR2 in metastatic lesions.

(J) Kaplan–Meier curves of the overall survival of mRCC patients, with regard to the expression levels of AdipoR2 in metastatic lesions.